Abstract
Sudden cardiac death (SCD) is a common cause of death in the general population, occurring in 300,000 to 350,000 people in the United States alone. Currently, there are no data supporting implantable cardioverter-defibrillator therapy in patients who underwent orthotopic heart transplant (OHT) with low left ventricular ejection fraction (LVEF). In this retrospective study, we included all patients who underwent primary OHT at our institution from 2007 to 2013. We compared the cause of death in patients who underwent OHT and evaluated the correlation of the cause of death and the patients' LVEF. Our objectives were to determine whether patients who underwent OHT with LVEF <35% are at increased risk for SCD compared with those who underwent OHT with normal LVEF. To summarize our results, a total of 345 patients were included in our study (mean age 50 ± 14 years, 68% men). The mean follow-up was 1,260 ± 698 days. Forty patients (11.5%) died >6 months after OHT. Surviving patients had higher LVEF compared with deceased patients (64 ± 7% and 50 ± 24%, respectively, p ≤0.001). In all, 10 (25%) of the deceased patients died suddenly, 9 (23%) from sepsis, and 8 (20%) from malignancy. Of the 11 deceased patients with LVEF ≤35%, 2 patients (18%) died suddenly compared with 9 SCDs among the 29 deceased patients (31%) with LVEF >35% (p = 0.54). In conclusion, patients who underwent OHT who died were more likely to have LVEF <35%, and a quarter of the deceased patients who underwent OHT died suddenly. A reduced LVEF was not associated with an increased risk of SCD.
Original language | English |
---|---|
Pages (from-to) | 1322-1326 |
Number of pages | 5 |
Journal | American Journal of Cardiology |
Volume | 117 |
Issue number | 8 |
DOIs | |
State | Published - 15 Apr 2016 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016 Elsevier Inc.
Funding
Dr. Birati—training and research grant support from HeartWare Ltd (Framingham, Massachusetts); Dr. Acker—consultant for HeartWare and Thoratec Corp. (Pleasanton, California); Dr. Rame—research support from Thoratec and HeartWare Ltd; Dr. Margulies—advisory committee membership for Novo Nordisk (Plainsboro, New Jersey) and Astra-Zeneca (Wilmington, Delaware) and research grant support from Juventis Therapeutics (Cleveland, Ohio), Celladon Corporation (San Diego, California), Thoratec Corporation, Innolign Biomedical (Philadelphia, Pennsylvania), LLC, and the US National Institutes of Health, Bethesda, Maryland (HL105993, HL110338, and HL113777); Dr. Goldberg—consultant to Thoratec, St. Jude and Respircardia; Drs Mathelier, Molina, Hanff, Mazurek, Atluri, and Jessup—none.
Funders | Funder number |
---|---|
HeartWare Ltd | |
Juventis Therapeutics | |
St. Jude and Respircardia | |
Thoratec Corp. | |
National Institutes of Health | HL105993, HL110338, HL113777 |
Thoratec Corporation | |
Celladon Corporation | |
HeartWare |